Teacher Retirement System of Texas Sells 20,979 Shares of Thermo Fisher Scientific Inc. $TMO

Teacher Retirement System of Texas cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 93,783 shares of the medical research company’s stock after selling 20,979 shares during the period. Teacher Retirement System of Texas’ holdings in Thermo Fisher Scientific were worth $54,343,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of TMO. Wellington Management Group LLP grew its position in Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock worth $1,309,292,000 after acquiring an additional 1,270,191 shares during the last quarter. Bank of New York Mellon Corp grew its position in Thermo Fisher Scientific by 54.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock worth $1,732,422,000 after acquiring an additional 1,262,967 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock worth $2,874,069,000 after buying an additional 1,028,125 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 89.1% in the 2nd quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock worth $720,576,000 after buying an additional 825,649 shares during the last quarter. Finally, Capital World Investors grew its position in shares of Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after buying an additional 706,572 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 beat on top‑ and bottom‑line — Revenue of $11.01B (+6.2% YoY) and non‑GAAP EPS of $5.44 exceeded Street estimates (revs ~$10.86B; EPS ~$5.25). This confirms solid core demand and margin resilience. Thermo Fisher Scientific Reports First Quarter 2026 Results
• Positive Sentiment: Strength in growth segments — Management highlighted lab products and biopharma services as growth drivers that offset weaker areas, supporting recurring revenue and higher‑margin service exposure. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Positive Sentiment: Analyst sentiment remains constructive — Consensus analyst rating is around “Moderate Buy,” indicating institutional expectations for continued earnings growth. Thermo Fisher Given Consensus Rating of “Moderate Buy”
• Neutral Sentiment: Company press release and detailed metrics available — The official release reiterates results, margins and KPIs for the quarter for investors wanting primary source detail. View Press Release
• Neutral Sentiment: Long‑term TAM and digital lab trends support growth — Market research highlights growth in cloud ELN and microbiology testing markets that play to Thermo Fisher’s product and services mix. Global Cloud ELN Service Market | Thermo Fisher
• Negative Sentiment: Shares slipped in premarket despite the beat — Immediate market reaction suggests investors focused on mixed segment performance, profit‑taking after recent gains, or expectations for stronger beats. Thermo Fisher slips in premarket despite beating Q1 forecasts
• Negative Sentiment: Softness in analytical instruments and specialty diagnostics may concern investors — Reuters flagged weakness in those areas, which could pressure growth if persistent. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Negative Sentiment: Technical and valuation considerations — TMO trades below its 200‑day SMA and carries a mid‑to‑high P/E (~29), which can amplify downside on mixed prints as investors rotate to cheaper or higher‑momentum names.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 1.8%

Shares of NYSE:TMO opened at $515.04 on Thursday. The stock has a fifty day simple moving average of $500.69 and a two-hundred day simple moving average of $550.56. The stock has a market capitalization of $191.40 billion, a price-to-earnings ratio of 29.03, a PEG ratio of 2.72 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio is 10.60%.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. DZ Bank initiated coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective on the stock. Wells Fargo & Company set a $683.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 30th. TD Cowen cut their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Finally, Barclays lowered their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $631.25.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.